Ps1070 the Echelon‐2 Trial: Results of a Randomized, Double‐blind Phase 3 Study of Brentuximab Vedotin and CHP (A+chp) Versus Chop in Frontline Treatment of Patients With Cd30+ Peripheral T‐cell Lymphomas
Abstract:m 2 , vincristine 1 mg on day 1 & prednisone 40 mg/m 2 or 100 mg/d x 5) followed by an additional two 21 day cycles of rituximab + ibrutinib (or high dose methotrexate for CNS prophylaxis). Pre-phase prednisone, quinolone prophylaxis during neutropenic period in cycle 1, and G-CSF each cycle were mandated. Deliverability is measured using Average Relative Total Dose (ARTD) [Average delivered dose of the chemotherapy regimen as a % of the target dose] and Average Relative Dose Intensity (ARDI)[Average delivered… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.